With the final hurdle for their $63 billion merger cleared in the EU, AbbVie and Allergan were in the home stretch to close the deal. Then the novel coronavirus took off, and now that merger could be further out of reach as regulatory bodies prepare to pump the brakes.
AbbVie and Allergan’s pending merger may face a regulatory delay after the Federal Trade Commission (FTC) and the U.S. Department of Justice’s (DOJ’s) antitrust division warned they may need additional time to review due to disruptions from COVID-19, Bloomberg reported Tuesday.
While the FTC said in a statement that its operations are running “without interruption,” the commission told Bloomberg that the two drugmakers could have issues producing documents and making employees available for review.
Full Content: Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Walmart Withdraws and Refiles Antitrust Review Application for Vizio Acquisition
Mar 28, 2024 by
CPI
Apple Prevails in Dismissal of Crypto-Payment Antitrust Lawsuit
Mar 27, 2024 by
CPI
Amazon Fined in Poland for Misleading Customers
Mar 27, 2024 by
CPI
Credit Card Rewards Under Threat as Visa, Mastercard Settlement Impacts Swipe Fees
Mar 27, 2024 by
CPI
UK Fashion Giants Commit to Honest Environmental Claims
Mar 27, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI